Ovagen Dosage, half-life & reference guide

Also known as Glu-Asp-Leu · EDL peptide

Reviewed Evidence: EmergingPublished by PepVault

A three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides. No human study has been published.

How often
Daily
Half-life
Unknown
Evidence
●●● Emerging
Routes
SubQ, Oral capsules

No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.

How it works.

A tripeptide, Glu-Asp-Leu (EDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers list for the liver and the kidneys. In rats with acute kidney injury, from the cancer drug cisplatin, the antibiotic gentamicin or a cut-off blood supply, EDL kept urine flowing, lowered protein and waste in the blood and urine and protected the kidneys' antioxidant enzymes, more strongly than the other peptides tested beside it. In the lab it binds DNA at particular sequences. No human study of Ovagen is indexed on PubMed, and its papers name it only by its sequence.

Commonly reported: Little to feel; user reports are few.

A smiling woman with silver hair in a grey training top by a window, holding her phone

PepVault for iPhone

Track ovagen in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Ovagen works.

A body with Gut lit
  • Gut

    In animals. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Not established (no human data)
Peak effect
Not established
Duration
Courses of 20–30 days (community practice)
  1. Day 1–14Community

    A quiet course

    Ovagen has no human studies, and users who share their runs mostly report little to feel. Commonly reported: mild discomfort where it goes in.

    Updated Nov 2026

  2. Day 14–60Animal

    What the rat kidney studies found

    In rats with acute kidney injury from drugs or a cut-off blood supply, EDL, the peptide in Ovagen, protected kidney function better than the related peptides tested beside it. If you have kidney blood work planned, it is the measure those studies used.

    The science

    Zamorskii 2015: in rats with cisplatin acute renal failure, the kidney polypeptide complex and EDL and AEDG normalized diuresis, urine creatinine, glomerular filtration and sodium reabsorption and lowered urine protein; EDL was the most potent. Zamorskii 2017: in gentamicin nephropathy and ischemia-reperfusion injury, EDL prevented oliguria and azotemia, lowered proteinuria and sodium loss, kept antioxidant enzymes up and normalized kidney energy supply.

    Sources
    • Zamorskii et al. (2015)
    • Zamorskii et al. (2017)

    Updated Nov 2026

  3. Any dayAnimal

    What Ovagen is built on

    A three-amino-acid peptide from the Russian bioregulator program, listed by its developers for the liver and kidneys. Its evidence is two rat studies of acute kidney injury and computer models of how it binds DNA; there is no human study.

    The science

    Khavinson 2021 review (Table 5): "EDL, Ovagen — regulation of renal cells' function, hepatoprotection, DNA binding". Zamorskii 2015 and 2017: rat kidney injury models. Khavinson 2016: in docking models, AEDL and EDL bind the ctcc sequence.

    Sources
    • Khavinson et al. (2021)
    • Zamorskii et al. (2015)
    • Zamorskii et al. (2017)
    • Khavinson et al. (2016)

    Updated Nov 2026

  4. With EpitalonCommunity

    Beside the pineal peptide

    Ovagen is commonly run beside other bioregulators, the pineal one among them. In the cisplatin kidney study, Epitalon's sequence (AEDG) also protected rat kidneys, less than EDL did. No study has given the two together.

    The science

    Zamorskii 2015: the kidney complex, EDL and AEDG normalized kidney measures in cisplatin-injured rats, EDL most potently. The pairing in stacks is community practice.

    Sources
    • Zamorskii et al. (2015)

    Updated Nov 2026

Day 1 is the day you start it.

No human study of Ovagen has been published. The effects come from two rat studies of acute kidney injury and from its developers' DNA models.

Preliminary research

A typical run.

Run notes

Cycle
Run in courses rather than continuously, like the other bioregulators: community capsule courses run 20–30 days, repeated every few months. No study in people has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
Timing
No timing has been studied.
Routes
SubQ injection, Oral capsules
Stacks
Epitalon

Track it in the app

Safety.

Common side effects

  • Injection-site discomfort

Interactions

No interaction studies exist, including with medicines that are hard on the kidneys or liver.

Safety notes

No safety study exists: no human study of Ovagen is indexed, so nothing is known about its side effects beyond user reports, or about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, or with a liver or kidney condition, which needs its own care.

Goes with.

Compared with.

Questions people ask.

What is Ovagen?

A three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys. In rats with acute kidney injury from drugs or a cut-off blood supply, it protected kidney function better than related peptides. No human study has been published.

How is Ovagen dosed in research?

The library carries no reference dose for Ovagen. No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.

How long does Ovagen last?

The half-life of Ovagen is unknown (never measured).

What do people report on Ovagen?

Commonly reported on Ovagen: little to feel; user reports are few.

Is Ovagen safe?

The research basis for Ovagen is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site discomfort.

What does Ovagen stack with?

Common stacks for Ovagen: Epitalon.

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Daily

Half-life

Unknown

Unknown (never measured)

Research basis

●●● Emerging

Primarily preclinical / limited human data

PepVault for iPhone

Track ovagen in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library